Psoriasis is a common inflammatory cutaneous disease that affects approximately 120
million people worldwide. Systemic treatments have significantly improved disease burden …

With its approval more than 15 years ago, subcutaneous etanercept (Enbrel®) was the first
biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis …

Approximately one in four patients treated with anti-TNF agents (infliximab, etanercept,
adalimumab, certolizumab, and golimumab) develops cutaneous adverse events, typically …

Several studies have described increased risk ratios of certain types of malignancies in
patients with severe psoriasis. Among these, the lymphoproliferative disorders, including …

Introduction: Anti-TNF-α therapy is a novel approach that has transformed the way moderate-
to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Background Psoriasis patients carry an increased risk for associated comorbidities.
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …

Introduction: The treatment of psoriasis with conventional topical therapies and disease-
modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the …

Objective The aim of this study was to describe 4 patients with oral mucosa
hyperpigmentation associated with 4 drug classes and to review the relevant literature …

Purpose Cutaneous melanoma is among the fastest growing malignancies in Norway and
ultraviolet radiation (UVR) exposure is the primary environmental risk factor …